Halozyme Therapeutics (HALO) Gross Profit (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Gross Profit data on file, last reported at $297.5 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $297.5 million, up 37.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 38.02% YoY), and the FY2025 annual result was $1.2 billion, up 36.44% from the prior year.
• Gross Profit retreated to $297.5 million in Q1 2026 per HALO's latest filing, from $373.0 million in the prior quarter.
• Over five years, Gross Profit peaked at $373.0 million in Q4 2025 and troughed at $101.4 million in Q1 2022.
• A 5-year average of $204.6 million and a median of $177.7 million in 2023 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2023: Gross Profit jumped 73.32% in 2022, then retreated 0.28% in 2023.
• A 5-year view of Gross Profit shows it stood at $139.4 million in 2022, then rose by 27.53% to $177.7 million in 2023, then soared by 44.0% to $256.0 million in 2024, then jumped by 45.73% to $373.0 million in 2025, then fell by 20.25% to $297.5 million in 2026.
• Business Quant data shows HALO's Gross Profit at $297.5 million in Q1 2026, $373.0 million in Q4 2025, and $299.0 million in Q3 2025.